The Powerhouse
Novavax Reports Second Quarter 2021 Financial Results and Operational Highlights
- Filed regulatory submissions for EUA in India, Indonesia and the Philippines, in partnership with Serum Institute of India
- Demonstrated greater than 4-fold increase in neutralizing antibody levels versus peak responses after primary vaccination in 6-month booster study
- Cross-reactive functional antibodies to Delta (B.1.617.2) variant detected after primary vaccination series and increased more than 6-fold upon boosting at 6 months
- Finalized APA with European Commission to supply up to 200 million doses
- Demonstrated high efficacy across variants in PREVENT-19 Phase 3 trial
- Announced positive results from first clinical study of influenza vaccine and COVID-19 vaccine candidate administered simultaneously
- On track to achieve 100 million dose monthly capacity by the end of the third quarter and 150 million dose monthly capacity by the end of the fourth quarter
- Company to host conference call today at 4:30 p.m. ET
GAITHERSBURG, Md., Aug. 5, 2021 /PRNewswire/ -- Novavax, Inc. (NASDAQ: NVAX), a biotechnology company developing next-generation vaccines for serious infectious diseases, today announced its financial results and operational highlights for the second quarter ended June 30, 2021.
"We are highly encouraged by the filing of regulatory submissions in multiple markets, made in partnership with Serum Institute of India. We view these submissions as the first of many filings to come, which will allow NVX-CoV2373 to be made available at a global scale," said Stanley C. Erck, President and Chief Executive Officer, Novavax. "Our clinical successes over the second quarter reaffirm our confidence in NVX-CoV2373's differentiated efficacy profile. We continue to see the circulation of new variants and inequitable access to vaccine globally, demanding that we bring our COVID-19 vaccine to market as swiftly as possible."
Second Quarter 2021 and Recent Highlights
COVID-19 Vaccine Clinical and Non-Clinical Development
Reported final analysis from PREVENT-19 U.S. and Mexico Phase 3 trial
Achieved primary efficacy endpoint with overall efficacy of 90.4% against mild, moderate, and severe disease
Demonstrated 100% protection against moderate and severe disease
Demonstrated 91.0% efficacy among high-risk populations
Demonstrated 92.6% efficacy against Variants of Concern/Variants of Interest (VoC/VoI) and 100% efficacy against variants not considered VoC/VoI
Completed enrollment of pediatric expansion of PREVENT-19 Phase 3 trial
Enrolled 2,248 adolescents aged 12-17 across up to 75 sites in the U.S.
Blinded crossover expected to begin in August 2021 to ensure all participants have access to active vaccine
Published results from late-stage South Africa Phase 2b and UK Phase 3 trials in The New England Journal of Medicine
Completed UK Phase 3 crossover arms and initiated crossover studies in PREVENT-19 and South Africa Phase 2b trials to ensure all participants have access to active vaccine
Advanced clinical development of booster studies of NVX-CoV2373
Reported 6-month booster data from U.S. and Australia Phase 2 trial
Wild-type neutralizing antibodies increased more than 4-fold versus primary vaccination series
Cross-reactive functional antibodies to the Delta (B.1.617.2) variant strain detected after primary vaccination series and increased more than 6-fold following boosting
Analysis of sera from primary series immunization showed cross-reactive functional antibodies to the Alpha (B.1.1.7), Beta (B.1.351), and Delta (B.1.617.2) variant strains, all of which increased 6- to 10-fold with a booster dose
Participated in two UK Vaccines Taskforce-supported studies evaluating heterologous vaccination (Com-COV2) and heterologous boosting (CoV-Boost)
COVID-19 Vaccine Regulatory Pathway
Filed regulatory submissions in partnership with Serum Institute of India Pvt. Ltd. (SII) for emergency use authorization in multiple markets
Submitted regulatory filings with the Drugs Controller General of India (DCGI) and regulatory agencies in Indonesia and the Philippines
Expect to file for Emergency Use Listing with the World Health Organization in August 2021
Expect to complete regulatory filing with the UK Medicines and Healthcare products Regulatory Agency (MHRA) in the third quarter of 2021
Expect to complete additional regulatory filings in other markets within weeks of MHRA filing, including with the European Medicines Agency (EMA), Australian Therapeutic Goods Administration, Health Canada, and New Zealand Medsafe
Expect to submit for emergency use authorization to the U.S. Food and Drug Administration in the fourth quarter of 2021
COVID-19 Vaccine Manufacturing and Supply
Collaborated with partners globally to progress toward anticipated manufacturing capacity
On track to achieve capacity of 100 million doses per month by the end of the third quarter of 2021 and 150 million doses per month by the end of the fourth quarter 2021
Initiated technology transfer at National Research Council of Canada Biologics Manufacturing Centre to produce NVX-CoV2373
Expanded agreements globally to ensure equitable access to low-, middle-, and high-income countries
Entered into advance purchase agreement with Gavi, the Vaccine Alliance, to provide 1.1 billion doses to the COVAX Facility
Novavax to manufacture and distribute 350 million doses
SII to manufacture and distribute the remaining balance of the 1.1 billion doses to low- and middle-income countries
Finalized terms of advance purchase agreement with European Commission to supply up to 100 million doses with the option for an additional 100 million doses through 2023
Delivery of doses to begin following anticipated regulatory approval from EMA
NanoFluTM / NVX-CoV2373 Combination Vaccine (qNIV/CoV2373)
Announced preclinical data for qNIV/CoV2373 and expect to initiate Phase 1 clinical trial in Australia later this year
qNIV/CoV2373 induced strong functional antibodies, high levels of anti-S IgG, and neutralizing antibody titers
Preclinical data manuscript submitted for publication to a peer-reviewed journal and posted via the preprint server on bioRxiv.org
Announced data from sub-study in UK Phase 3 trial, supporting co-administration of NVX-CoV2373 with influenza vaccination
431 participants received approved seasonal influenza vaccine, while half of those participants were co-vaccinated with NVX-CoV2373
Co-administration did not negatively impact influenza immune response for any of the four influenza strains in the quadrivalent influenza vaccine
Confirmed efficacy trend of 87.5% against COVID-19
Data manuscript submitted for publication to a peer-reviewed journal and posted via the preprint server on medRxiv.org
Malaria Vaccine / Matrix-M™ Adjuvant Collaboration
Ongoing clinical development for R21, the University of Oxford's malaria vaccine candidate formulated with Matrix-M™ adjuvant, in collaboration with SII
Phase 3 licensure trial underway in 4,800 participants, aged 5-36 months
Phase 2b clinical trial results demonstrated 77% efficacy and were published in Preprints with The Lancet
Financial Results for the Three Months Ended June 30, 2021
Novavax reported a net loss of $352 million, or $4.75 per share, for the second quarter of 2021, compared to a net loss of $18 million, or $0.30 per share, for the second quarter of 2020.
Novavax revenue in the second quarter of 2021 was $298 million, compared to $36 million in the same period in 2020. This increase was due to increased development activities relating to NVX-CoV2373 for services performed under the U.S. government and Coalition for Epidemic Preparedness Innovations agreements.
Research and development expenses increased to $571 million in the second quarter of 2021, compared to $35 million in the same period in 2020. The increase was primarily due to the development of NVX-CoV2373.
General and administrative expenses increased to $73 million in the second quarter of 2021, compared to $18 million for the same period in 2020. The increase was primarily due to increased employee-related costs, stock-based compensation expenses, and professional fees supporting our NVX-CoV2373 program.
As of June 30, 2021, Novavax had $2.1 billion in cash, cash equivalents and restricted cash, compared to $806 million as of December 31, 2020. Net cash provided by operating activities for the first six months of 2021 was $807 million, compared to $93 million for the same period in 2020. The increase in cash provided was primarily due to $1.1 billion in payments under advance purchase agreements recorded as deferred revenue and the timing of payments to third parties.
Through utilization of At-the-Market (ATM) offerings during the first six months of 2021, Novavax raised net proceeds of $565 million.
Conference Call
Novavax will host its quarterly conference call today at 4:30 p.m. ET. The dial-in numbers for the conference call are (866) 652-5200 (Domestic) or (412) 317-6060 (International). Participants will be prompted to request to join the Novavax, Inc. call. A replay of the conference call will be available starting at 7:30 p.m. ET on August 5, 2021 until 7:30 p.m. ET on November 12, 2021. To access the replay by telephone, dial (877) 344-7529 (Domestic) or (412) 317-0088 (International) and use passcode 10158313.
A webcast of the conference call can also be accessed on the Novavax website at novavax.com/events. A replay of the webcast will be available on the Novavax website until November 12, 2021.
About NVX-CoV2373
NVX-CoV2373 is a protein-based vaccine candidate engineered from the genetic sequence of the first strain of SARS-CoV-2, the virus that causes COVID-19 disease. NVX-CoV2373 was created using Novavax' recombinant nanoparticle technology to generate antigen derived from the coronavirus spike (S) protein and is formulated with Novavax' patented saponin-based Matrix-M™ adjuvant to enhance the immune response and stimulate high levels of neutralizing antibodies. NVX-CoV2373 contains purified protein antigen and can neither replicate, nor can it cause COVID-19. In preclinical studies, NVX-CoV2373 induced antibodies that blocked the binding of spike protein to cellular receptors and provided protection from infection and disease. It was generally well-tolerated and elicited robust antibody response in Phase 1/2 clinical testing.
NVX-CoV2373 is being evaluated in two pivotal Phase 3 trials: a trial in the U.K. that demonstrated efficacy of 96.4% against the original virus strain, 86.3% against the Alpha (B.1.1.7) variant and 89.7% efficacy overall; and the PREVENT-19 trial in the U.S. and Mexico that demonstrated 100% protection against moderate and severe disease and 90.4% efficacy overall. It is also being tested in two ongoing Phase 2 studies that began in August 2020: A Phase 2b trial in South Africa that demonstrated 55% efficacy overall in HIV-negative participants and 48.6% efficacy against a newly emerging escape variant first described in South Africa, and a Phase 1/2 continuation in the U.S. and Australia.
NVX-CoV2373 is stored and stable at 2°- 8°C, allowing the use of existing vaccine supply chain channels for its distribution. It is packaged in a ready-to-use liquid formulation in 10-dose vials.
